Discontinuation reactions following sertraline.
Leiter
F L
FL
Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA.
Nierenberg
A A
AA
Sanders
K M
KM
Stern
T A
TA
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001288:Attention / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005684:Gait / Q000187:drug effects; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007508:Irritable Mood; D008297:Male; D020280:Sertraline; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014012:Tinnitus / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D000928:Antidepressive Agents; D015057:1-Naphthylamine; D020280:Sertraline